IHS Chemical Week

Regions :: North America :: U.S.

Mallinckrodt to acquire Cadence Pharmaceuticals

2:09 AM MST | February 13, 2014 | Natasha Alperowicz

Mallinckrodt, a specialty pharmaceutical and medical imaging group, says that it has entered into a definitive agreement to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00/share in cash, or approximately $1.3 billion. Subject to terms and conditions, the parties expect the transaction to close in mid- to late March. Mallinckrodt says it expects the acquisition to be immediately accretive to its fiscal 2014 adjusted diluted earnings per share and significantly accretive to its fiscal 2015 adjusted diluted earnings per share.   Cadence is...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa